Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.

ABSTRACT:

SUBMITTER: van de Donk NWCJ 

PROVIDER: S-EPMC11494165 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature